IBM (NYSE: IBM) recently announced a new initiative to accelerate the adoption of genomic based medicine at Cleveland Clinic. Researchers at Cleveland Clinic will use IBM Watson technology in the area of genomic research to help oncologists deliver personalized medicine by uncovering new cancer treatment options for patients.
Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, recently announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).
MolecularMatch Announces Innovative Solution to Connect Cancer Patients with the Most Effective Treatments and Clinical Trials
MolecularMatch, Inc. recently announced it has launched its innovative software solution as an open Beta information service for oncologists and patients to easily connect cancer patients with the most appropriate FDA-approved treatments and clinical trials based on the molecular make-up of the patient’s disease.
sphingotec and GeneNews Limited/Innovative Diagnostics Laboratory (IDL) Sign a Licensing and Cooperation Agreement for the U.S. Market
sphingotec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, recently announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and sphingotest® pro-ENK—to GeneNews Limited (TSX:GEN). The biomarker assays will aid physicians in risk assessment for breast cancer in females in the general population. sphingotec discovers and develops blood tests to detect cancer, cardiovascular conditions and kidney disease in high-risk patients.
Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip
Antigen Discovery Inc. (ADi), a privately held company in Irvine, California, announced the receipt of a National Institutes of Health (NIH) Phase I Small Business Innovation Research award (SBIR) from the National Institute of Dental and Craniofacial Research (NIDCR). The one-year $225,000 award will fund the development of a Pan-HIV Protein Microarray Chip, which will contain every protein in all of the HIV-1 and HIV-2 subtypes and aid in the development of safe and effective vaccines and therapies to prevent HIV infection.